Sunshine Biopharma (SBFM) said Wednesday that it completed additional studies of its K1.1 mRNA lipid nanoparticle product, which confirmed it as a novel therapeutic agent for liver cancer.
Under repeated dosing, the mRNA product was found to reduce the growth of three different types of human hepatocellular carcinoma tumors in mice, with good tolerability, the company said.
The company said it is now conducting additional studies to define the optimum dosing of truncated version of the product, which is said to offer better efficacy at lower doses.
Sunshine Biopharma shares were 49% higher in recent premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。